VIVA BIOTECH (01873): Langhua Pharmaceutical's Environmental Impact Report Gains Approval

Stock News01-29

VIVA BIOTECH (01873) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., recently received a response from the Taizhou Municipal Bureau of Ecology and Environment regarding the environmental impact report submitted for the proposed production of certain peptide and other small-molecule drug advanced intermediates. This response approves Langhua Pharmaceutical's plan, as detailed in the environmental impact report, to renovate three existing plants within the Zhejiang Chemical Raw Material Drug Base in Linhai Park to manufacture these advanced intermediates for peptides and other small-molecule drugs. Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact report, adhering to the requirements specified in the response and managing the project in compliance with relevant laws and regulations, aiming to commence production as soon as feasibly possible. The production plan is expected to drive the Group's business growth and enhance its production capabilities and capacity, thereby benefiting the Group. The company hereby states that it has not made any forecasts or predictions regarding the impact of this production plan on the Group's profits.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140170464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140170464","market":"nz","top_or_hot":-1,"title":"VIVA BIOTECH (01873): Langhua Pharmaceutical's Environmental Impact Report Gains Approval","media":"Stock News","content":"<p>VIVA BIOTECH (01873) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., recently received a response from the Taizhou Municipal Bureau of Ecology and Environment regarding the environmental impact report submitted for the proposed production of certain peptide and other small-molecule drug advanced intermediates. This response approves Langhua Pharmaceutical's plan, as detailed in the environmental impact report, to renovate three existing plants within the Zhejiang Chemical Raw Material Drug Base in Linhai Park to manufacture these advanced intermediates for peptides and other small-molecule drugs. Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact report, adhering to the requirements specified in the response and managing the project in compliance with relevant laws and regulations, aiming to commence production as soon as feasibly possible. The production plan is expected to drive the Group's business growth and enhance its production capabilities and capacity, thereby benefiting the Group. The company hereby states that it has not made any forecasts or predictions regarding the impact of this production plan on the Group's profits.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VIVA BIOTECH (01873): Langhua Pharmaceutical's Environmental Impact Report Gains Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVIVA BIOTECH (01873): Langhua Pharmaceutical's Environmental Impact Report Gains Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-29 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VIVA BIOTECH (01873) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., recently received a response from the Taizhou Municipal Bureau of Ecology and Environment regarding the environmental impact report submitted for the proposed production of certain peptide and other small-molecule drug advanced intermediates. This response approves Langhua Pharmaceutical's plan, as detailed in the environmental impact report, to renovate three existing plants within the Zhejiang Chemical Raw Material Drug Base in Linhai Park to manufacture these advanced intermediates for peptides and other small-molecule drugs. Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact report, adhering to the requirements specified in the response and managing the project in compliance with relevant laws and regulations, aiming to commence production as soon as feasibly possible. The production plan is expected to drive the Group's business growth and enhance its production capabilities and capacity, thereby benefiting the Group. The company hereby states that it has not made any forecasts or predictions regarding the impact of this production plan on the Group's profits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1140170464","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140170464","pubTimestamp":1769685995,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIVA BIOTECH (01873) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., recently received a response from the Taizhou Municipal Bureau of Ecology and Environment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1191":"制药","BK1574":"生物医药B类股","01477":"欧康维视生物-B"},"translate_title":"维亚生物(01873)：朗华制药环境影响报告书获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1,"01477":1},"content_text":"VIVA BIOTECH (01873) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., recently received a response from the Taizhou Municipal Bureau of Ecology and Environment regarding the environmental impact report submitted for the proposed production of certain peptide and other small-molecule drug advanced intermediates. This response approves Langhua Pharmaceutical's plan, as detailed in the environmental impact report, to renovate three existing plants within the Zhejiang Chemical Raw Material Drug Base in Linhai Park to manufacture these advanced intermediates for peptides and other small-molecule drugs. Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact report, adhering to the requirements specified in the response and managing the project in compliance with relevant laws and regulations, aiming to commence production as soon as feasibly possible. The production plan is expected to drive the Group's business growth and enhance its production capabilities and capacity, thereby benefiting the Group. The company hereby states that it has not made any forecasts or predictions regarding the impact of this production plan on the Group's profits.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140170464","isCrawlerRequest":true}